BioMarin Lifts Full-Year Outlook as Q2 Revenue Climbs 20% to $990M on Robust VOXZOGO Demand

summarizeSummary

BioMarin posted Q2 2026 revenue of $990 million, a 20% year-over-year increase, and raised full-year guidance for total revenues, VOXZOGO, and Non-GAAP EPS. The Amicus acquisition is driving growth, while pipeline advances include a submitted sNDA for VOXZOGO in hypochondroplasia and an FDA acceptance for full achondroplasia approval.

check_boxKey Events · Earnings and Guidance · BMRN

• Q2 Revenue Surges 20% to $990M

  Driven by VOXZOGO ($253M, +14% YoY) and the newly acquired GALAFOLD and POMBILITI + OPFOLDA, total revenues reached $990 million. Metabolic Conditions revenue grew 25% year-over-year.

• Full-Year Guidance Raised Across the Board

  Management lifted 2026 total revenue guidance to $3.875B–$3.925B (midpoint +21% YoY), VOXZOGO guidance to $1.0B–$1.05B, and Non-GAAP diluted EPS guidance to $4.90–$5.10.

• Amicus Acquisition Drives Growth and Synergies

  The $4.8B Amicus acquisition closed April 27, 2026. BioMarin expects $280M in GAAP cost synergies by 2028 and peak revenues of ~$1.4B for GALAFOLD and ~$1.2B for POMBILITI + OPFOLDA.

• Pipeline Catalysts: VOXZOGO sNDA Submitted, PDUFA Set

  A supplemental NDA for VOXZOGO in hypochondroplasia has been submitted. The FDA accepted the sNDA for full achondroplasia approval with a PDUFA target action date of February 28, 2027.

auto_awesomeAnalysis · BMRN · Life Sciences

A 20% year-over-year revenue surge to $990 million underscored BioMarin's strong second quarter, fueled by global VOXZOGO demand and the newly acquired GALAFOLD and POMBILITI + OPFOLDA products. Reflecting that momentum, management raised full-year 2026 guidance across the board: total revenues are now expected between $3.875 billion and $3.925 billion, VOXZOGO revenue is guided to at least $1 billion, and Non-GAAP diluted EPS is lifted to $4.90–$5.10. The Amicus acquisition, which closed in April, is already contributing meaningfully, with $280 million in GAAP cost synergies targeted by 2028. Pipeline catalysts are building as well—a supplemental NDA for VOXZOGO in hypochondroplasia has been submitted, and the FDA accepted the sNDA for full approval in achondroplasia with a PDUFA date of February 28, 2027. On the bottom line, GAAP net income fell sharply to $45 million from $241 million a year ago, weighed down by acquisition-related costs, intangible amortization, and higher interest expense from the $4.8 billion Amicus deal. Non-GAAP income, which strips out those one-time items, declined 16% to $236 million, reflecting higher R&D and commercial spend. The stock is trading near its 52-week high, suggesting the market had already priced in much of the good news, but the raised guidance and pipeline catalysts provide a clear path for continued growth.